TRIGR Therapeutics to Present at Biotech Showcase™ During JP Morgan Healthcare Conference, San Francisco, January 2019By: TRIGR Therapeutics 
TRIGR Rx Time: Wednesday January 9th, 2019 at 8:45am Pacific Time Room: Franciscan D (Ballroom Level) Venue: Hilton San Francisco Union Square, 333 O'Farrell Street, San Francisco, CA Miranda Toledano, CFO, will provide an overview of the Company and discuss its clinical development and business strategy. TRIGR will also be available for partnering discussions and investor meetings during the JP Morgan Healthcare Conference being held January 7th to January 10th 2019 in San Francisco. About TRIGR Therapeutics TRIGR is an emerging biotechnology company in the field of immuno-oncology therapies that was incorporated in April 2018 and managed by biopharmaceuticals industry veterans (Roche, Abraxis, Merck, Sanofi Aventis, Pfizer). TRIGR focuses on clinical development and commercialization of next generation targeted immuno-oncology drugs for the Asian, US and European markets. The Company's pipeline includes a clinical stage dual-angiogenesis bispecific antibody program (TR009) and pre-clinical dual checkpoint and immune engaging bispecific antibodies targeting 4-1BB, PDL1, BCMA, B7H4 and LAG3. Contact: George Uy, CEO & Founder, guy@TrigrRx.com Miranda Toledano, CFO, Miranda.toledano@ http://www.trigrrx.com/ Photo: https://www.prlog.org/ End
|
Account Phone Number